Veeva Network for compiling physician master-data lists and related prescriber data has initial customers
Veeva (Pleasanton, CA), said to be the fastest-growing CRM vendor in life sciences, went public on the NY Stock Exchange on Oct. 16; initially priced at $20 per share, the company’s stock popped 87% in its first day, closing at $37.37, while generating $261 million for the company.
In the runup and now subsequent to its IPO, the company is shifting its identity from a CRM vendor riding the iPad wave to a “cloud services for life sciences” company, says newly promoted president, Matt Wallach. It has followed through on announcements made this spring to add services for organizing and storing drug-development and promotional material (in Veeva Vault), and a HIPPA-compliant email service for physicians and pharma reps, as well as Veeva Network for compiling master databases on physician identities, addresses and affiliations. “We’re transitioning from basic CRM sales software to becoming the industry’s preferred cloud services, software and data provider,” he says.
Veeva Network, which now has four bipharma companies in its early-adopter program, presents an especially intriguing potential. Wallach says that life sciences customers it has approached are uniformly enthusiastic about sharing their master data on physicians—a form of “crowdsourcing” in which the pooled results benefit all participants. In theory, as Veeva CRM clients input their routine sales call data into Veeva repositories, those data will quickly become an accurate, up-to-the-minute database of physician locations, contact information, licensure and email addresses, with professional affiliations also a strong possibility. Currently, a dozen or so vendors sell these master data lists to manufacturers; for Veeva customers, those data essentially become free. To this end, the company acquired one of these master-date vendors, AdvantageMS, earlier this year, and is building similar capabilities outside the US (the company currently has offices in nine countries.)
In practice, says Wallach, the basic master data will be shared, but each Veeva client will be able to create its own data-field extensions to store proprietary data on, for example, physician response to sales messaging. At some point—but not yet—Veeva Network will be available to non-CRM clients.
Protecting Temperature-Sensitive Pharmaceuticals, Without Unnecessary Plastic Waste
March 24th 2025Advances in the life sciences are driving a significant increase in the number of temperature-sensitive pharmaceuticals. The packaging industry is meeting the moment with advances of its own, including high-performance, environmentally-friendly materials that allow life science companies meet stringent thermal requirements and ambitious CO2e reduction goals. In this episode, TemperPack’s CEO Peter Wells shares insights from working with life sciences to move to certified biobased, home compostable, and curbside recyclable shipping solutions.
Protect Temperature-Sensitive Pharmaceuticals Without the Unnecessary Plastic Waste
March 24th 2025Peter Wells, CEO of TemperPack, discusses the life sciences industry's shift toward sustainable packaging, particularly in cold chain logistics, to replace outdated petroleum-based materials like expanded polystyrene (EPS). His insights cover the growing importance of sustainability as a business driver, emphasizing efficiency, waste reduction, regulatory pressures, and emerging innovations in biodegradable and recyclable packaging solutions.